Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure
- 21 March 2022
- journal article
- research article
- Published by Springer Nature in Journal of Medical Toxicology
- Vol. 18 (3) , 187-197
Abstract
Introduction Atropine sulfate is an FDA-approved medical countermeasure (MCM) for the treatment of organophosphorus nerve agent and organophosphate pesticide toxicity. Sufficient MCM supplies must be available in an incident involving a mass human exposure either from an accidental chemical release or a terrorist attack. Methods We performed a randomized, 3-sequence, 3-period phase I crossover study to assess the bioavailability and pharmacokinetics (PK) of a single dose (0.5 mg and 1.0 mg) of 1% ophthalmic atropine sulfate solution administered sublingually to 15 healthy adult volunteers. The primary endpoint was evaluation of the bioavailability of each of the two sublingual doses against a 1.0 mg reference intravenous (IV) atropine dose. Secondary endpoints included the safety and tolerability (xerostomia scale) of atropine sulfate administered sublingually. Results Sublingual atropine was safe (no severe AEs or SAEs were reported with either dose) and well tolerated, with a single subject reaching maximum xerostomia on a single dosing day. The geometric mean AUC∞ was 286.40, 493.81, and 816.47 min*ng/mL for the 0.5 mg and 1.0 mg sublingual doses, and the 1.0 mg IV dose, respectively. Compared to IV administration, the 1.0 mg sublingual dose produced 0.60 (90% CI: 0.55–0.66) of the overall concentration of atropine over time (AUC∞). Conclusion Sublingual atropine sulfate 1% ophthalmic solution may be an alternative formulation and route of administration combination which expands the capacity and dosing options of atropine as a nerve agent MCM.Keywords
This publication has 14 references indexed in Scilit:
- Sublingual administration of atropine eyedrops in children with excessive drooling – a pilot studyInternational Journal of Paediatric Dentistry, 2015
- Randomized Double-Blind Trial of Sublingual Atropine vs. Placebo for the Management of Death RattleJournal of Pain and Symptom Management, 2013
- Development of atropine sulphate nasal drops and its pharmacokinetic and safety evaluation in healthy human volunteersEnvironmental Toxicology and Pharmacology, 2009
- Pretreating Rats with Parenteral Ophthalmic Antimuscarinic Agents Decreases Mortality from Lethal Organophosphate PoisoningAcademic Emergency Medicine, 2007
- Atropine drops for drooling: a randomized controlled trialPalliative Medicine, 2006
- Speed of Initial Atropinisation in Significant Organophosphorus Pesticide Poisoning—A Systematic Comparison of Recommended RegimensJournal of Toxicology: Clinical Toxicology, 2004
- Atropine availability as an antidote for nerve agent casualties: Validated rapid reformulation of high-concentration atropine from bulk powderAnnals of Emergency Medicine, 2003
- Sublingual Atropine for sialorrhea secondary to parkinsonism: A pilot studyMovement Disorders, 2002
- Development of a Visual Analogue Scale questionnaire for subjective assessment of salivary dysfunctionOral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology, 2001
- The Tokyo Subway Sarin Attack: Disaster Management, Part 2: Hospital Response*Academic Emergency Medicine, 1998